Navin Fluo.Intl. Q1 FY27 Earnings Call — Analysis (NSE: NAVINFLUOR)

Navin Fluorine reports 44% YoY revenue growth and 73% EBITDA growth in Q1 FY27, announces ₹90 Cr advanced materials adoption capex and ₹125 Cr CDMO Phase 2 capex, with all three business segments performing strongly.

11 Aug 2026 · Analysis by Alpha Inflection

Result quality: strong — Margin expansion. Management sentiment: optimistic.

The take

Q1FY27 Revenue ₹1,045 Cr ( +44% YoY ) . New guidance — FY27 cdmo business revenue $100 million . New story: Advanced Materials Vertical Incubation .

Results

Revenue ₹1,045 Cr +44% YoY; EBITDA ₹357 Cr +73% YoY; PAT ₹243 Cr +108% YoY; EBITDA margin 34.2% (+566 bps YoY).

Financial highlights

Guidance

CDMO FY27 revenue target of $100 million remains on track; margins expected to be in the 32-33% range over the next one to two years.

What management committed to

• [Chemours liquid cooling project] targeted for completion by end of Q2 FY27. — Q2FY27
• [cGMP4 Phase 2 capacity] expected to operationalize by Q4 FY27. — Q4FY27
• [HFC R32 capacity expansion] of up to 15,000 metric tons remains on track for commissioning in Q3 FY27. — up to 15,000 metric tons, Q3FY27
• MPP debottlenecking at Dahej expected to be completed by Q3 FY27. — Q3FY27
• Advanced Materials adoption capacity capex of ₹90 Cr to be completed overall by Q2 FY28 (first phase by mid-Q4 FY27). — ₹90 Cr, Q2FY28
• CDMO business will achieve revenue of $100 million in FY27; the target is very much on track and likely to be exceeded. — $100 million, FY27
• CDMO revenue from cGMP4 (Phase 1+2) capacity will achieve asset turn of 3x by FY29, implying ~₹864 Cr revenue from that capacity. — 3x (implied ~₹864 Cr), FY29
• [Management aims to] contract 35% to 45% of total R32 capacity on a five-year basis. — 35-45%
• Consolidated EBITDA margin will be in the range of 32% to 33% plus/minus 1% over the next one to two years, supported by operating leverage. — 32-33% plus/minus 1%, next one to two years
• At least three molecules from the CDMO pipeline are expected to go to an FDA readout over the next 8 to 12 months. — 3 molecules, Q2FY28
• Once operational, the 14.9 MW hybrid renewable project will meet more than 60% of [Navin Fluorine's] energy requirements. — >60%

Key themes

Broad-based growth, capex-led capacity expansion, and advanced materials incubation

How the narrative shifted

• Advanced Materials Vertical Incubation: Company is investing in niche fluorination applications for high-growth sectors (data centers, electronics, defence, semiconductors) to build it into a material business by decade-end, initially via adoption platforms and strategic partnerships like Chemours and DRDO.
• CDMO Deepening and Broadening: Baseload from European CDMO partner is deepening (API minus-1, new molecule MSA) while the molecule pipeline broadens across 30-40 programs, multiple innovators and diverse therapeutic areas, positioning CDMO as a high-growth engine with clear asset-turn targets.
• R32 Supply-Demand and Contracting Strategy: Long-term R32 demand will double while quota-driven supply shrinks; Navin aims to lock 35-45% capacity under five-year contracts while leveraging lowest-cost position to outperform regardless of near-term pricing volatility.
• Operating Leverage and Margin Resilience: New capacities (HFC, MPP, CDMO, Chemours) and productivity initiatives (renewable power, debottlenecking) will drive operating leverage, keeping EBITDA margins in a 32-33% sweet spot despite raw material inflation.
• Capex Discipline and Balance Sheet Strength: Capex is funded through internal accruals, net debt has turned to zero, and investments follow stage-gated approvals with clear asset-turn expectations, derisking growth.
• Spec Chem Recovery via Innovator-Led Approach: Specialty chemicals navigates generic agchem pricing pressure by deepening relationships with innovators, launching patented molecules, and achieving 2x asset turns on debottlenecking projects.
• Macro and Raw Material Headwinds: Global geopolitical tensions and supply-chain risks are raising raw material costs; management is focused on passing through increases where pricing power exists and offsetting via productivity.

Operational commentary

• Advanced Materials adoption capacity: Board approved ₹90 Cr capex to create two core platforms at Surat for indigenous products targeting data centers, electronics, semiconductors and defence; first phase by mid-Q4 FY27, overall completion by Q2 FY28; five products already lab-approved moving to commercial scale qualification.
• CDMO Phase 2 capex: ₹125 Cr approved (part of earlier ₹288 Cr cGMP4) to be operational by Q4 FY27, dedicated to a European CDMO partner, extending from API-minus-1 position and adding an extra molecule in the same supply chain.
• HFC capacity expansion: Additional R32 capacity of up to 15,000 MT on track for commissioning in Q3 FY27; management confident in long-term demand-supply gap and cost competitiveness.
• MPP debottlenecking: Dahej MPP debottlenecking progressing well, expected completion Q3 FY27 with a targeted 2x asset turn.
• CDMO pipeline: 30–40 molecules actively worked on; ~10 in late stage; 3–4 molecules expected to achieve FDA readout in next 8–12 months; therapeutic areas include oncology, cardiovascular, respiratory, neurology, animal health.
• HFC contractual offtake: Increasing customer interest; aim to lock 35–45% of total R32 capacity under five-year contracts to provide visibility while retaining open exposure.
• Specialty chemicals: Robust order visibility; 5 new molecule campaign orders in FY27, including 3 patented molecules with innovators, offsetting generic agchem pricing pressure.
• Renewable energy: ₹15.73 Cr investment in group captive hybrid project for 14.9 MW, expected to meet >60% of energy requirements once operational.
• Chemours project: On track for completion by end Q2 FY27; remains the only manufacturing site for Chemours' two-phase cooling fluid, contributing to Advanced Materials vertical.
• Balance sheet: Operating cash flow ₹173 Cr; company turned net debt free during the quarter.
• DRDO partnership: Technology development project for indigenous specialty material, part of Advanced Materials vertical, with applications beyond defence.

Analyst Q&A

• Q. Details on DRDO order and its impact on revenues and margins

  We can only share what is already public due to confidentiality, but the product has applications beyond defence which present a material opportunity for Navin.

• Q. R32 pricing outlook and impact of upcoming Indian capacities on CY27

  Pricing is not in our control, but we remain the lowest-cost producer; operating leverage from additional 15,000 MT will protect EBITDA growth and margins in any pricing environment. Global demand-supply gap will favour low-cost producers over the next five years.

• Q. Clarification on cGMP4 asset turn and CDMO revenue trajectory

  FY29 3x asset turn on the ₹288 Cr cGMP4 capex is correct, and overall CDMO revenue (including earlier cGMPs) would be even higher.

• Q. Reason for margin contraction in subsidiary NFASL and impact on consolidated margins

  NFASL’s AHF capacity has been commissioned, shifting transfer pricing from value-added products to HF on an arm’s length basis; group-level margins remain solid. Further downstream expansions at NFASL will make it margin accretive.

• Q. Advanced Materials adoption capex asset turn and payback timeline

  It's a seeding investment with five lab-approved products; commercial scale qualification will generate revenue and payback quickly, but no explicit asset turn is being disclosed at this stage.

View source

Research and educational content only. Not investment advice.